Evidence map›Paper›PMID 24670147›Full record

ArticleBritish journal of pharmacology2014

The ryanodine receptor agonist 4-chloro-3-ethylphenol blocks ORAI store-operated channels.

Bo Zeng, Gui-Lan Chen, Nikoleta Daskoulidou, Shang-Zhong Xu

Open access · greenAbstract read
In one paragraph

Article in British journal of pharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.3field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Mibefradil, a T-type CaBritish journal of pharmacology · 2019
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Bo ZengCentre for Cardiovascular and Metabolic Research, Hull York Medical School, University of Hull, Hull, UK.
Gui-Lan Chen
Nikoleta Daskoulidou
Shang-Zhong Xu
Hull York Medical School · GBSouthwest Medical University · CNUniversity of Hull · GB

Funding

British Heart Foundation PG/08/071/25473British Heart Foundation PG08/071/25473
6 · The paper itself

Abstract

backgroundDepletion of the Ca(2+) store by ryanodine receptor (RyR) agonists induces store-operated Ca(2+) entry (SOCE). 4-Chloro-3-ethylphenol (4-CEP) and 4-chloro-m-cresol (4-CmC) are RyR agonists commonly used as research tools and diagnostic reagents for malignant hyperthermia. Here, we investigated the effects of 4-CEP and its analogues on SOCE. EXPERIMENTAL APPROACH: SOCE and ORAI1-3 currents were recorded by Ca(2+) imaging and whole-cell patch recordings in rat L6 myoblasts and in HEK293 cells overexpressing STIM1/ORAI1-3. KEY

results4-CEP induced a significant release of Ca(2+) in rat L6 myoblasts, but inhibited SOCE. The inhibitory effect was concentration-dependent and more potent than its analogues 4-CmC and 4-chlorophenol (4-ClP). In the HEK293 T-REx cells overexpressing STIM1/ORAI1-3, 4-CEP inhibited the ORAI1, ORAI2 and ORAI3 currents evoked by thapsigargin. The 2-APB-induced ORAI3 current was also blocked by 4-CEP. This inhibitory effect was reversible and independent of the Ca(2+) release. The two analogues, 4-CmC and 4-ClP, also inhibited the ORAI1-3 channels. Excised patch and intracellular application of 4-CEP demonstrated that the action site was located extracellularly. Moreover, 4-CEP evoked STIM1 translocation and subplasmalemmal clustering through its Ca(2+) store-depleting effect via the activation of RyR, but no effect on STIM1 redistribution was observed in cells co-expressing STIM1/ORAI1-3. CONCLUSION AND IMPLICATIONS: 4-CEP not only acts as a RyR agonist to deplete the Ca(2+) store and trigger STIM1 subplasmalemmal translocation and clustering, but also directly inhibits ORAI1-3 channels. These findings demonstrate a novel pharmacological property for the chlorophenol derivatives that act as RyR agonists.

Indexed as

AnimalsCalciumCalcium Channel AgonistsCalcium ChannelsCell LineChlorophenolsCresolsHEK293 CellsHumansMembrane ProteinsNeoplasm ProteinsORAI1 ProteinORAI2 ProteinRatsRyanodine Receptor Calcium Release ChannelStromal Interaction Molecule 14-chloro-3-ethylphenol4-chlorophenolCalciumCalcium Channel AgonistsCalcium ChannelschlorocresolChlorophenolsCresolsMembrane ProteinsNeoplasm ProteinsORAI1 ProteinORAI1 protein, humanORAI2 ProteinORAI2 protein, humanOrai3 protein, humanRyanodine Receptor Calcium Release ChannelSTIM1 protein, humanStromal Interaction Molecule 14-chloro-3-ethylphenol4-chloro-m-cresolORAIryanodine receptorsSTIM1store-operated Ca2+ channels

Identifiers

PMID24670147
PMCPMC3952802
OpenAlexW1569016688

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.